JGC
CYTK icon

J. Goldman & Co’s Cytokinetics CYTK Stock Holding History

J. Goldman & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.45M Buy
+67,500
New +$4.29M 0.13% 202
2024
Q4 		– Sell
-20,300
Closed -$1.07M – 500
2024
Q3 		$1.07M Buy
+20,300
New +$1.13M 0.03% 288

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

J. Goldman & Co's CYTK Position: Q1 2026 in Review

J. Goldman & Co reduced its Cytokinetics (CYTK) stake by 32% in Q1 2026, selling an estimated $358K and leaving 12,007 shares worth $791K. The position accounts for 0.02% of the portfolio, ranked #451.

J. Goldman & Co first reported a position in CYTK in Q1 2023 and has held it in 8 quarters since. The position peaked at $3.72M in Q1 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • J. Goldman & Co held 12,007 shares of Cytokinetics worth $791K as of Q1 2026.
  • J. Goldman & Co sold 5,638 Cytokinetics shares in Q1 2026, an estimated $358K.
  • Cytokinetics made up 0.02% of J. Goldman & Co's portfolio in Q1 2026, its #451 holding.
  • J. Goldman & Co first reported a position in Cytokinetics in Q1 2023 and has held it in 8 quarters since.
  • J. Goldman & Co's Cytokinetics position peaked at $3.72M in Q1 2023.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.